These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15170583)

  • 1. [Preoperative cardiovascular risk evaluation--diagnosis].
    Cremers B; Maack C; Böhm M
    Dtsch Med Wochenschr; 2004 May; 129(22):1256-9. PubMed ID: 15170583
    [No Abstract]   [Full Text] [Related]  

  • 2. Pre-operative cardiac risk assessment in noncardiac surgery: are natriuretic peptides the magic bullet?
    Bolliger D; Seeberger MD; Filipovic M
    J Am Coll Cardiol; 2009 Oct; 54(17):1607-8. PubMed ID: 19833259
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical utility of the cardiac markers BNP and NT-proBNP].
    Buchner S; Riegger G; Luchner A
    Acta Med Austriaca; 2004; 31(4):144-51. PubMed ID: 15732251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal-pro-B-type natriuretic peptide: universal marker of cardiovascular risk?
    Richards AM; Frampton CM
    Circulation; 2005 Jul; 112(1):9-11. PubMed ID: 15998694
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preoperative evaluation of patients with cardiovascular disorders].
    Todokoro S
    Masui; 1999; 48 Suppl():S117-25. PubMed ID: 10785970
    [No Abstract]   [Full Text] [Related]  

  • 6. Preoperative plasma N-terminal pro-brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non-cardiac surgery (Br J Surg 2005; 92: 1041-1045).
    Gibson S; Berry C; Kingsmore D
    Br J Surg; 2005 Nov; 92(11):1453-4. PubMed ID: 16237747
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
    Giannitsis E
    Clin Lab; 2005; 51(1-2):63-83. PubMed ID: 15719708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker sensitivity and specificity require pre-test probability of disease diagnosis to be collated: additional points on the interpretation of pro-B-type natriuretic peptide triage of dyspnea in the Copenhagen Heart Study.
    MacFadyen RJ; Chuen MJ
    J Am Coll Cardiol; 2008 Apr; 51(13):1322-3; author reply 1323. PubMed ID: 18371568
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T.
    Sommerer C; Giannitsis E; Schwenger V; Zeier M
    Nephron Clin Pract; 2007; 107(3):c77-81. PubMed ID: 17890874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natriuretic peptides in heart failure: their role in daily practice.
    Loboz-Grudzień K; Jaroch J
    Cardiol J; 2009; 16(1):1-3. PubMed ID: 19130409
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preoperative cardiovascular risk evaluation--therapy].
    Cremers B; Maack C; Böhm M
    Dtsch Med Wochenschr; 2004 May; 129(22):1260-4. PubMed ID: 15170584
    [No Abstract]   [Full Text] [Related]  

  • 12. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes.
    Galvani M; Ottani F; Oltrona L; Ardissino D; Gensini GF; Maggioni AP; Mannucci PM; Mininni N; Prando MD; Tubaro M; Vernocchi A; Vecchio C;
    Circulation; 2004 Jul; 110(2):128-34. PubMed ID: 15197143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple biomarkers and cardiovascular risk.
    Austin MJ; Heneghan MA
    N Engl J Med; 2008 Aug; 359(7):760-1; author reply 761. PubMed ID: 18711791
    [No Abstract]   [Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation in autoimmune diseases: algorithm for cardiovascular assessment.
    Miniati I; Conforti ML; Bernardo P; Tyndall A; Gensini GF; Matucci-Cerinic M
    Herz; 2007 Feb; 32(1):43-50. PubMed ID: 17323034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease.
    Hess G; Runkel S; Zdunek D; Hitzler WE
    Clin Lab; 2005; 51(3-4):167-72. PubMed ID: 15819172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cardiac biomarkers in end-stage renal disease.
    Wang AY; Lai KN
    J Am Soc Nephrol; 2008 Sep; 19(9):1643-52. PubMed ID: 18322158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.
    Olsen MH; Hansen TW; Christensen MK; Gustafsson F; Rasmussen S; Wachtell K; Ibsen H; Torp-Pedersen C; Hildebrandt PR
    Eur Heart J; 2007 Jun; 28(11):1374-81. PubMed ID: 17242007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study.
    Schnabel R; Rupprecht HJ; Lackner KJ; Lubos E; Bickel C; Meyer J; Münzel T; Cambien F; Tiret L; Blankenberg S;
    Eur Heart J; 2005 Feb; 26(3):241-9. PubMed ID: 15618051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide.
    Jarai R; Iordanova N; Jarai R; Raffetseder A; Woloszczuk W; Gyöngyösi M; Geyer G; Wojta J; Huber K
    Eur Heart J; 2005 Feb; 26(3):250-6. PubMed ID: 15618049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative plasma N-terminal pro-brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non-cardiac surgery (Br J Surg 2005; 92: 1041-1045).
    Brady RR; Ryan M
    Br J Surg; 2005 Dec; 92(12):1566; author reply 1566. PubMed ID: 16308866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.